Trial Search Results

Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Aduro Biotech, Inc.

Collaborator: Hanlee P. Ji, MD

Stanford Investigator(s):


  • Biological: pLADD


Phase 1


Inclusion Criteria:

   - metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)

   - able to provide adequate tumor tissue from at least 1 accessible tumor site

   - completed or have developed intolerance to a course of oxaliplatin- or
   irinotecan-based frontline therapy at Screening

   - on maintenance standard-of-care chemotherapies or on treatment holiday

   - Eastern Cooperative Oncology Group (ECOG) 0 or 1

   - adequate organ function

   - progression of disease at the time of Enrollment

Exclusion Criteria:

   - BRAF V600E mutation

   - known allergy to both penicillin and sulfa drugs

   - implanted devices that cannot be easily removed

   - immunodeficiency, immune compromised state or receiving immunosuppressive therapy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting